Updated 2025-2026 formulations of mRNA-1283 and BNT162b2 protect older adults against severe COVID-19 outcomes and medically attended illness.

Fecal microbiota transplantation may offer short-term improvements in motor function and constipation severity for adults with Parkinson disease.

The association between elevated interferon α and Sjögren disease sheds new light on immune pathways and disease.

Polyendocrine metabolic ovarian syndrome is associated with a higher incidence of atherosclerotic cardiovascular disease events.

Unfavorable sleep profiles and weaker rest-activity rhythms are associated with a higher prevalence of overactive bladder.

Expanded genetic testing for amyotrophic lateral sclerosis may increase the demand for longitudinal surveillance of asymptomatic gene carriers.

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

An outside advisory panel to the FDA is pushing for the production and sale of a few previously banned peptide treatments.

A 2026 guideline on the management of dyslipidemia expands recommendations for primary prevention statin therapy among the US population.

Perampanel offers meaningful seizure control and an acceptable safety profile for patients with brain tumor-related epilepsy, a new review shows.

Many adults born with a very low birth weight or very preterm exhibit lower positive functioning in early adulthood.

Molecular profiling, biomarker detection, and in vivo imaging are reshaping how neurologists diagnose neurodegenerative ...